Finding the best treatment for lung TB (PARADIGM4TB)
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests different ways to treat active lung TB that is not resistant to rifampicin. It aims to find the best treatment duration and combination to cure TB and prevent it from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have active TB in your lungs (confirmed by symptoms, chest X-ray, or sputum test)
- Your sputum test (Xpert Ultra) shows a 'medium' or 'high' amount of TB bacteria and no resistance to rifampicin
- Your weight is between 30 and 100 kg (about 66 to 220 pounds) and your BMI is between 15 and 40
- You are willing to attend all study visits, take your medication as directed, and live at an address the study team can visit
- You have not taken more than 1 dose of TB medication in the last 14 days, and you do not have certain health problems (like heart issues, seizures, or active cancer)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests treatment for people with newly diagnosed, drug-susceptible pulmonary (lung) tuberculosis (TB). It aims to see whether the study treatment works well and is safe for curing TB.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests new combinations of TB medicines for people with active lung TB that is sensitive to standard drugs. It aims to find safer, shorter treatments that work just as well or better than current options.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This study tests a shorter-course treatment for tuberculosis (TB) in people 65 and older. It compares a new ultra-short regimen to the usual longer one, using the drugs bedaquiline, linezolid, and pyrazinamide, to see if a shorter treatment is just as effective and safer for older adults.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
Hear when a new Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.